Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P van der Bruggen

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Bulletin Et Memoires De L'Academie Royale De Medecine De Belgique|July 30, 2010
[Is it possible to correct the anergy of T lymphocytes that infiltrate tumors?]P van der Bruggen
Clinical Immunology and Immunopathology|June 1, 1994
The long-standing quest for tumor rejection antigensP van der Bruggen
Tissue Antigens|April 4, 2000
A MAGE-A1 peptide is recognized on HLA-B7 human tumors by cytolytic T lymphocytesR Luiten, P van der Bruggen
The Journal of Experimental Medicine|March 1, 1996
Human tumor antigens recognized by T lymphocytesT Boon, P van der Bruggen
Gene|January 31, 1997
Mitochondrial DNA polymerases from yeast to man: a new family of polymerasesN Lecrenier, P Van Der Bruggen, F Foury
Current Opinion in Immunology|October 1, 1992
Molecular definition of tumor antigens recognized by T lymphocytesP van der Bruggen, B Van den Eynde
Current Opinion in Immunology|November 22, 1997
T cell defined tumor antigensB J Van den Eynde, P van der Bruggen
Journal of Immunology (Baltimore, Md. : 1950)|February 7, 2001
A human CTL recognizes a caspase-8-derived peptide on autologous HLA-B*3503 molecules and two unrelated peptides on allogeneic HLA-B*3501 moleculesS Mandruzzato, V Stroobant, N Demotte, et al.
European Journal of Immunology|July 31, 1999
Effect of epitope flanking residues on the presentation of N-terminal cytotoxic T lymphocyte epitopesU Gileadi, A Gallimore, P Van der Bruggen, et al.
Melanoma Research|August 1, 1997
MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyteB Lethé, P van der Bruggen, F Brasseur, et al.
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Bulletin Et Memoires De L'Academie Royale De Medecine De Belgique|July 30, 2010
[Is it possible to correct the anergy of T lymphocytes that infiltrate tumors?]P van der Bruggen
Clinical Immunology and Immunopathology|June 1, 1994
The long-standing quest for tumor rejection antigensP van der Bruggen
Tissue Antigens|April 4, 2000
A MAGE-A1 peptide is recognized on HLA-B7 human tumors by cytolytic T lymphocytesR Luiten, P van der Bruggen
The Journal of Experimental Medicine|March 1, 1996
Human tumor antigens recognized by T lymphocytesT Boon, P van der Bruggen
Gene|January 31, 1997
Mitochondrial DNA polymerases from yeast to man: a new family of polymerasesN Lecrenier, P Van Der Bruggen, F Foury
Current Opinion in Immunology|October 1, 1992
Molecular definition of tumor antigens recognized by T lymphocytesP van der Bruggen, B Van den Eynde
Current Opinion in Immunology|November 22, 1997
T cell defined tumor antigensB J Van den Eynde, P van der Bruggen
Journal of Immunology (Baltimore, Md. : 1950)|February 7, 2001
A human CTL recognizes a caspase-8-derived peptide on autologous HLA-B*3503 molecules and two unrelated peptides on allogeneic HLA-B*3501 moleculesS Mandruzzato, V Stroobant, N Demotte, et al.
European Journal of Immunology|July 31, 1999
Effect of epitope flanking residues on the presentation of N-terminal cytotoxic T lymphocyte epitopesU Gileadi, A Gallimore, P Van der Bruggen, et al.
Melanoma Research|August 1, 1997
MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyteB Lethé, P van der Bruggen, F Brasseur, et al.
Pageof 7